Epstein-Barr_JJ
virus_NN
-LRB-_-LRB-
EBV_NN
-RRB-_-RRB-
replicative_JJ
gene_NN
expression_NN
in_IN
tumor_NN
cells_NNS
of_IN
AIDS-related_JJ
non-Hodgkin_JJ
's_POS
lymphoma_NN
in_IN
relation_NN
to_TO
CD4_NN
cell_NN
number_NN
and_CC
antibody_NN
titers_NNS
to_TO
EBV_NN
._.

OBJECTIVE_NN
:_:
To_TO
determine_VB
whether_IN
activation_NN
of_IN
Epstein-Barr_JJ
virus_NN
-LRB-_-LRB-
EBV_NN
-RRB-_-RRB-
replication_NN
in_IN
tumor_NN
cells_NNS
of_IN
AIDS-related_JJ
non-Hodgkin_JJ
's_POS
lymphoma_NN
-LRB-_-LRB-
ARNHL_NN
-RRB-_-RRB-
is_VBZ
correlated_VBN
with_IN
CD4_NN
+_CC
cell_NN
counts_NNS
and_CC
influences_VBZ
antibody_NN
response_NN
to_TO
EBV_NN
-LCB-_-LRB-
anti-Z_JJ
Epstein-Barr_JJ
replicative_JJ
activator_NN
-LRB-_-LRB-
ZEBRA_NN
-RRB-_-RRB-
,_,
anti-early_JJ
antigen_NN
-LRB-_-LRB-
EA_NN
-RRB-_-RRB-
,_,
anti-viral_JJ
capsid_NN
antigen_NN
-LRB-_-LRB-
VCA_NN
-RRB-_-RRB-
-RCB-_-RRB-
._.

DESIGN_NN
:_:
Retrospective_JJ
study_NN
based_VBN
on_IN
immunohistochemistry_NN
and_CC
in_FW
situ_FW
hybridization_NN
to_TO
detect_VB
EBV_NN
replicative_JJ
gene_NN
products_NNS
in_IN
tissue_NN
samples_NNS
from_IN
patients_NNS
affected_VBN
by_IN
ARNHL_NN
and_CC
correlation_NN
with_IN
CD4_NN
+_CC
cell_NN
counts_NNS
and_CC
results_NNS
of_IN
EBV_NN
serology_NN
-LRB-_-LRB-
including_VBG
anti-ZEBRA_JJ
activity_NN
-RRB-_-RRB-
in_IN
sera_NN
from_IN
the_DT
same_JJ
patients_NNS
._.

METHODS_NNS
:_:
Seventeen_CD
out_IN
of_IN
22_CD
cases_NNS
of_IN
ARNHL_NN
were_VBD
selected_VBN
for_IN
the_DT
presence_NN
of_IN
EBV_NN
-LCB-_-LRB-
Epstein-Barr_JJ
early_JJ
region_NN
-LRB-_-LRB-
EBER_NN
-RRB-_-RRB-
RNA-positive_JJ
-RCB-_-RRB-
._.

Immunohistochemistry_NN
was_VBD
performed_VBN
with_IN
anti-ZEBRA_JJ
,_,
anti-EA-restricted_JJ
,_,
anti-VCA_JJ
antibodies_NNS
and_CC
in_FW
situ_FW
hybridization_NN
with_IN
BHLF1\/NotI_NN
oligoprobes_NNS
on_IN
tumor_NN
samples_NNS
._.

Results_NNS
were_VBD
statistically_RB
correlated_VBN
with_IN
those_DT
of_IN
CD4_NN
+_CC
cell_NN
counts_NNS
-LRB-_-LRB-
17_CD
out_IN
of_IN
17_CD
-RRB-_-RRB-
and_CC
with_IN
anti-EBV_JJ
antibody_NN
titers_NNS
-LRB-_-LRB-
13_CD
out_IN
of_IN
17_CD
-RRB-_-RRB-
assessed_VBN
using_VBG
standard_JJ
immunofluorescence_NN
method_NN
and_CC
enzyme-linked_JJ
immunosorbent_JJ
assay_NN
procedure_NN
using_VBG
recombinant_JJ
ZEBRA_NN
protein_NN
and_CC
synthetic_JJ
peptides_NNS
as_IN
antigens_NNS
._.

RESULTS_NNS
:_:
BZLF1_NN
-LRB-_-LRB-
ZEBRA_NN
-RRB-_-RRB-
or_CC
early_JJ
gene_NN
products_NNS
-LRB-_-LRB-
EA-R_NN
and_CC
EA-D\/BHLF1\/NotI_NN
-RRB-_-RRB-
were_VBD
detected_VBN
in_IN
a_DT
small_JJ
proportion_NN
-LRB-_-LRB-
&lt;_JJR
0.01-5_CD
%_NN
-RRB-_-RRB-
of_IN
tumor_NN
cells_NNS
in_IN
eight_CD
of_IN
these_DT
17_CD
cases_NNS
by_IN
immunohistochemistry_NN
and_CC
in_FW
situ_FW
hybridization_NN
._.

Demonstration_NN
of_IN
replicative_JJ
gene_NN
expression_NN
did_VBD
not_RB
correlate_VB
with_IN
either_CC
low_JJ
CD4_NN
+_CC
cell_NN
counts_NNS
-LRB-_-LRB-
P_NN
&gt;_JJR
0.05_CD
-RRB-_-RRB-
or_CC
anti-EBV_JJ
antibody_NN
titers_NNS
-LRB-_-LRB-
P_NN
&gt;_JJR
0.05_CD
-RRB-_-RRB-
._.

Anti-ZEBRA_JJ
activity_NN
was_VBD
not_RB
significantly_RB
increased_VBN
in_IN
patients_NNS
affected_VBN
with_IN
ARNHL_NN
,_,
the_DT
cells_NNS
of_IN
which_WDT
expressed_VBD
replicative_JJ
gene_NN
products_NNS
-LRB-_-LRB-
P_NN
&gt;_JJR
0.05_CD
-RRB-_-RRB-
._.

CONCLUSION_NN
:_:
The_DT
degree_NN
of_IN
immunodeficiency_NN
does_VBZ
not_RB
clearly_RB
enhance_VB
replicative_JJ
gene_NN
expression_NN
in_IN
tumor_NN
cells_NNS
of_IN
ARNHL_NN
._.

EBV_NN
serology_NN
,_,
including_VBG
anti-ZEBRA_JJ
activity_NN
,_,
is_VBZ
not_RB
a_DT
reliable_JJ
tool_NN
for_IN
predicting_VBG
the_DT
occurrence_NN
of_IN
such_JJ
proliferations_NNS
._.

